Innovative Pharmaceutical Biotech Limited (0399.HK)
HKD 0.19
(0.53%)
HKD 0.19
(0.53%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.27 Million | -17.64 Million | -12.33 Million | -25 Million | -36.22 Million | -29.49 Million |
| Net Income | 103.4 Million | -254.67 Million | 36.43 Million | -212.15 Million | -222.46 Million | -260.91 Million |
| Depreciation & Amortization | 941 Thousand | 1.88 Million | 2.13 Million | 2.3 Million | 1.24 Million | 67 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.27 Million | 1.36 Million | 9.88 Million | -6 Million | -5.16 Million | -10.01 Million |
| Other non-cash items | -114.17 Million | 233.78 Million | -60.78 Million | 190.84 Million | 190.15 Million | 241.36 Million |
| Investing Cash Flow | - | - | -1000.00 | 13 Thousand | 49.97 Million | 10.86 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | 13 Thousand | 50 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | 50 Million | 10.65 Million |
| Other Investing Activities | - | - | -1000.00 | 13 Thousand | -50.02 Million | 205 Thousand |
| Financing Cash Flow | 10.32 Million | 14.92 Million | 7.29 Million | 10.57 Million | -9.47 Million | 15.45 Million |
| Debt repayment | -11.3 Million | -1.88 Million | -12.61 Million | -2.3 Million | -25 Million | -15.48 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 11.3 Million | 16.8 Million | 19.91 Million | 12.87 Million | 15.52 Million | 30.93 Million |
| Accounts receivables | 1.32 Million | 3.27 Million | 6.14 Million | 211 Thousand | 5.33 Million | -8.65 Million |
| Accounts payables | -2.16 Million | -4.13 Million | 2.67 Million | -4.77 Million | -10.96 Million | 10.8 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.12 Million | 2.21 Million | 1.06 Million | -1.43 Million | 465 Thousand | -12.16 Million |
| Cash at beginning of period | 1.33 Million | 4.08 Million | 8.99 Million | 22.93 Million | 17.05 Million | 20.22 Million |
| Cash at end of period | 3.07 Million | 1.33 Million | 4.08 Million | 8.99 Million | 22.93 Million | 17.05 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -298 Thousand | -33 Thousand | 129 Thousand | 476 Thousand | 1.6 Million | 3000.00 |
| Net cash flow / Change in cash | 1.74 Million | -2.75 Million | -4.9 Million | -13.94 Million | 5.87 Million | -3.16 Million |
| Free Cash Flow | -8.27 Million | -17.64 Million | -12.33 Million | -25 Million | -36.22 Million | -29.49 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 103.4 Million | -45.14 Million | -45.14 Million | 193.68 Million | 96.84 Million | -254.67 Million |
| Depreciation & Amortization | 941 Thousand | 94 Thousand | 94 Thousand | 753 Thousand | 376.5 Thousand | 1.88 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.27 Million | 3.22 Million | 3.22 Million | - | - | 1.36 Million |
| Other non-cash items | -114.17 Million | 39.87 Million | 39.87 Million | -197.31 Million | -99.4 Million | 233.78 Million |
| Investing Cash Flow | - | - | - | 21 Thousand | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 10.32 Million | 3.22 Million | 3.22 Million | 3.86 Million | 1.93 Million | 14.92 Million |
| Debt repayment | -11.3 Million | - | - | - | - | -1.88 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 11.3 Million | 3.22 Million | 3.22 Million | 4.8 Million | 1.93 Million | 16.8 Million |
| Accounts receivables | 1.32 Million | 664 Thousand | 664 Thousand | - | - | 3.27 Million |
| Accounts payables | -2.16 Million | - | - | - | - | -4.13 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.12 Million | 2.56 Million | 2.56 Million | - | - | 2.21 Million |
| Cash at beginning of period | 1.33 Million | 862 Thousand | - | 1.33 Million | - | 4.08 Million |
| Cash at end of period | 3.07 Million | 3.07 Million | 1.1 Million | 862 Thousand | -234.5 Thousand | 1.33 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -298 Thousand | -170 Thousand | -170 Thousand | 21 Thousand | 21 Thousand | -33 Thousand |
| Net cash flow / Change in cash | 1.74 Million | 2.21 Million | 1.1 Million | -469 Thousand | -234.5 Thousand | -2.75 Million |
| Free Cash Flow | -8.27 Million | -1.95 Million | -1.95 Million | -4.37 Million | -2.18 Million | -17.64 Million |
7177
7822
AKEL-D
LAM
AOIFF
TCS